Using our SHM-Platform™, AnaptysBio is building a pipeline of novel therapeutic antibody product candidates that represent best in class opportunities, have significant medical and commercial potential, and in some cases are directed against disease targets for which other technology platforms have often failed to generate therapeutically useful antibodies.